Aquestive Therapeutics to Present Anaphylm Progress at Piper Sandler Healthcare Conference
Aquestive Therapeutics Inc. will present the regulatory progress and commercial readiness of Anaphylm™ at the Piper Sandler Healthcare Conference in New York City from December 2-4, 2025. A fireside chat is scheduled for December 4, 2025, at 10:00 a.m. ET, with a webcast available on their website. Investor meetings will also be held on the same day.
Aquestive Therapeutics Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference, taking place from December 2-4, 2025, in New York City. The company’s management team is scheduled for a fireside chat on December 4, 2025, at 10:00 a.m. ET, where they will discuss the regulatory progress and commercial readiness of their product candidate Anaphylm™ (dibutepinephrine) sublingual film. Additionally, management will host investor meetings on the same day. A webcast of the discussion will be available on the Aquestive Therapeutics website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9580443-en) on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
